These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 6233925)

  • 1. The biological activity of antithrombotic agents immobilized on polymer surfaces.
    Kim SW; Ebert CD; McRea JC; Briggs C; Byun SM; Kim HP
    Ann N Y Acad Sci; 1983; 416():513-24. PubMed ID: 6233925
    [No Abstract]   [Full Text] [Related]  

  • 2. Heparin neutralization of PGI2: effects upon platelets.
    Saba HI; Saba SR; Blackburn CA; Hartmann RC; Mason RG
    Science; 1979 Aug; 205(4405):499-501. PubMed ID: 377493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of sulphated polysaccharides on prostacyclin (prostaglandin I2)-induced inhibition of platelet aggregation [proceedings].
    Kindness G; Williamson FB; Long WF
    Biochem Soc Trans; 1980 Jun; 8(3):377-9. PubMed ID: 6995209
    [No Abstract]   [Full Text] [Related]  

  • 4. Heparin opposes prostanoid and non-prostanoid platelet inhibitors by direct enhancement of aggregation.
    MacIntyre DE; Handin RI; Rosenberg R; Salzman EW
    Thromb Res; 1981 Apr 1-15; 22(1-2):167-75. PubMed ID: 6270842
    [No Abstract]   [Full Text] [Related]  

  • 5. Fibrinogen-immobilized urokinase demonstrates increased thrombolytic activity in animal experiments.
    Maksimenko AV; Samarenko MB; Petrov AD; Tischenko EG; Ruda MYa ; Torchilin VP
    Ann N Y Acad Sci; 1990; 613():479-82. PubMed ID: 1706154
    [No Abstract]   [Full Text] [Related]  

  • 6. Immobilization of urokinase on agarose matrices.
    Kim HP; Byun SM; Yeom YI; Kim SW
    J Pharm Sci; 1983 Mar; 72(3):225-8. PubMed ID: 6221088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The action of antithrombin III on plasmin and activators of plasminogen.
    Crawford GP; Ogston D
    Biochim Biophys Acta; 1975 May; 391(1):189-92. PubMed ID: 124592
    [No Abstract]   [Full Text] [Related]  

  • 8. [Combined effects of PGI2 and thrombin inhibitors or fibrinolytic agent on platelet aggregation and disaggregation].
    Takahashi H; Nagayama R; Fuse I; Hattori A; Shibata A
    Rinsho Ketsueki; 1984 Jul; 25(7):998-1003. PubMed ID: 6389931
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of PGI2 on platelet aggregation induced by various stimulants.
    Ohtsu A; Hoshina K; Kurozumi S; Hashimoto Y; Noguchi T; Nicolaou KC
    Nihon Ketsueki Gakkai Zasshi; 1979 Aug; 42(4):659-66. PubMed ID: 388963
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluation of prostaglandin and prostacyclin antagonism at platelet receptors by aggregometry.
    Eggerman TL; Harker LA; Andersen NH; Wilson CH
    Adv Prostaglandin Thromboxane Res; 1980; 6():389-93. PubMed ID: 6247888
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of recombinant-tissue plasminogen activator, low molecular weight urokinase and unfractionated heparin on platelet aggregation.
    Paolini R; Casonato A; Boeri G; Luzzatto G; Girolami A; Sasahara AA; Cella G
    J Med; 1993; 24(2-3):113-30. PubMed ID: 8409776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Characteristics of effect of fibrinolysis system on ADP- and serotonin-dependent human thrombocyte aggregation].
    Men'shikov MIu
    Biull Eksp Biol Med; 1998 Feb; 125(2):158-61. PubMed ID: 9559126
    [No Abstract]   [Full Text] [Related]  

  • 13. [Effect of heparin and prostacyclin on blood platelet activity].
    Kisiel S; Myśliwiec M; Jakubowska I; Rydzewski A
    Pol Tyg Lek; 1983 Jun; 38(24):717-20. PubMed ID: 6359097
    [No Abstract]   [Full Text] [Related]  

  • 14. A prospective method for thrombotic diseases using prostaglandin I2.
    Isobe J; Mizuno A
    Tokushima J Exp Med; 1982 Jun; 29(1-2):95-101. PubMed ID: 6755803
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of prostacyclin, 6-keto-PGF1 alpha PGF2 alpha and 15[S]15-methyl-PGF2 alpha on platelet aggregation in vitro.
    Marmo E; Somma A; Ottavo R; Vairo G; Spaziante G; DiMezza F; Paone G
    J Med; 1981; 12(2-3):97-108. PubMed ID: 7024451
    [No Abstract]   [Full Text] [Related]  

  • 16. Water-soluble urokinase derivatives of combined action.
    Maksimenko AV; Torchilin VP
    Thromb Res; 1985 May; 38(3):277-88. PubMed ID: 4024043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro inhibition by endotoxin of the anti-aggregatory action of prostacyclin produced by aortic rings.
    Bult H; Herman AG
    Arch Int Pharmacodyn Ther; 1978 Aug; 234(2):335-6. PubMed ID: 361006
    [No Abstract]   [Full Text] [Related]  

  • 18. Novel 7-oxabicyclo[2.2.1]heptane prostacyclin agonists.
    Haslanger MF; Sprague PW; Snitman D; Vu T; Harris DN; Greenberg R; Powell J
    Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():293-7. PubMed ID: 6221540
    [No Abstract]   [Full Text] [Related]  

  • 19. The in vitro and in vivo behavior of urokinase immobilized onto collagen-synthetic polymer composite material.
    Watanabe S; Shimizu Y; Teramatsu T; Murachi T; Hino T
    J Biomed Mater Res; 1981 Jul; 15(4):553-63. PubMed ID: 7024280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Platelet sensitivity to prostacyclin (PGI2) in patients with juvenile-onset diabetes mellitus (author's transl)].
    Klein K; Sinzinger H; Schernthaner G; Silberbauer K; Prager R
    Wien Klin Wochenschr; 1981 Jul; 93(14):460-2. PubMed ID: 7023074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.